Price$3.23+0.15 (+4.87%)
02:00 PM06:15 PM
News · 26 weeks46+33%
2025-12-142026-06-07
Mix2790d
- Insider10(37%)
- Other9(33%)
- SEC Filings6(22%)
- Earnings2(7%)
Latest news
25 items- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- PRNasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study in Third Quarter of 2026 TEL AVIV, Israel, June 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a preclinical pharmacokinetic ("PK") and safety study of NS003, the Company's proprietary intranasal powder formulation of ondansetron being developed for chemotherapy and post-operative nausea and vomiting. Ondanse
- PRNasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of AnaphylaxisTEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that it will host a virtual key opinion leader ("KOL") event on Wednesday, June 10, 2026 at 8:00 AM ET featuring Michael S. Blaiss, MD (Medical College of Georgia, Good Samaritan Health Center of Gwinnett) and Joel Brooks, DO, MPH (Columbia University Vagelos College of Physicians and Surgeons, New York-Presbyterian Morgan Stanley Children's Hospital), who will join members of the Company's management to discuss the unmet need and current treatment landscape
- SECSEC Form S-8 filed by Nasus Pharma Ltd.S-8 - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form SCHEDULE 13G filed by Nasus Pharma Ltd.SCHEDULE 13G - Nasus Pharma Ltd (0002029039) (Subject)
- PRNasus Pharma to Participate in Upcoming Investor ConferencesTEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences. Market Movers Investor SummitMay 5, 2026, New York, NYChief Financial Officer Eyal Rubin will participate in 1x1 meetings. D. Boral Capital Global ConferenceMay 7, 2026, New York, NYChief Financial Officer Eyal Rubin will participate in 1x1 meetings. Interested investors should contact their respective representatives at the sponsoring institutions to request meetings. About Nasu
- INSIDERSEC Form 4 filed by Teleman Dan Benjamin4 - Nasus Pharma Ltd (0002029039) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Nasus Pharma Ltd.SCHEDULE 13G - Nasus Pharma Ltd (0002029039) (Subject)
- INSIDERSEC Form 4 filed by Teleman Dan Benjamin4 - Nasus Pharma Ltd (0002029039) (Issuer)
- SECSEC Form EFFECT filed by Nasus Pharma Ltd.EFFECT - Nasus Pharma Ltd (0002029039) (Filer)
- INSIDERSEC Form 3 filed by new insider Rubin Eyal3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Teleman Dan Benjamin3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Silberman David3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hershman Ronnie3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shacham Sharon3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gilboa Udi3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Megiddo Dalia3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Israel Isaac3 - Nasus Pharma Ltd (0002029039) (Issuer)
- SECSEC Form POS AM filed by Nasus Pharma Ltd.POS AM - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form 20-F filed by Nasus Pharma Ltd.20-F - Nasus Pharma Ltd (0002029039) (Filer)
- PRNasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business UpdateRecent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026 Company advancing pipeline assets NS003 (Ondansetron for chemotherapy-induced nausea and vomiting) and NS004 (metabolic) toward first-in-human studies expected to start in the second half of 2026, significantly expanding the Company's intranasal product portfolio into additional high value therapeutic areas Company well funded through planned NS002 pivotal study and potential NDA submission TEL AVIV, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSR
- PRBriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar TranscriptIn a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. The study demonstrated a statistically significant and clinically meaningful advantage over EpiPen in time to therapeutic threshold (T100), with NS002 reaching effective epinephrine levels in a median of 1.69 minutes compared to 3.42 minutes for EpiPen. At 2.5 minutes, 67.4% of participants receiving NS002 had already reached therapeutic levels versus 27.1% with EpiPen, with the advantage persisting through the 5-minute mark. Across the critical early treatment wind
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- PRNasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic ThresholdNS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 Conference call and webcast scheduled for 8:00 a.m. EDT today TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"),
NSRX FAQ
5 questionsWhere does NSRX stock trade?
Nasus Pharma Ltd. (NSRX) is listed on AMEX.What sector and industry is NSRX in?
Nasus Pharma Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nasus Pharma Ltd. go public?
Nasus Pharma Ltd. (NSRX) completed its IPO in 2025.What companies are similar to NSRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NSRX side-by-side with any of them on Quantisnow.How can I track NSRX on Quantisnow?
Quantisnow aggregates Nasus Pharma Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NSRX to receive live email and push alerts on every new disclosure.